RxDoctor Payments Data

Richard Salinas, PA

Physician Assistant · West Palm Beach, FLNPI 1265049530

Payments from drug & device makers

$2,328in general payments, 2019–2025

Across 104 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$570
  • Astellas Pharma US Inc$492
  • Johnson & Johnson$202
  • Esperion Therapeutics, Inc.$190
  • Novartis$155
  • Vanda Pharmaceuticals Inc.$142
  • plus $576 from 11 others

What the payments were for

  • Food & beverage$1,94283%
  • Education$38617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,328 in reported general payments places this provider in the 75th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$9,033
Medicare patients
71
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate68$75,413
OzempicSemaglutide43$54,192
JardianceEmpagliflozin27$32,221
EliquisApixaban17$28,867
EntrestoSacubitril/Valsartan12$17,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,713
XareltoRivaroxaban14$16,559
TrulicityDulaglutide13$12,211
Breo ElliptaFluticasone/Vilanterol18$11,890
Albuterol Sulfate HfaAlbuterol Sulfate80$2,959
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp19$2,934
Atorvastatin Calcium203$1,732
Rosuvastatin Calcium69$1,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,600
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$1,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$88$75,41368 claims
Novo NordiskOzempic$15$54,19243 claims
Boehringer IngelheimJardiance$37$32,22127 claims
GSKTrelegy Ellipta, Breo Ellipta$39$28,60331 claims
NovartisEntresto$155$17,12712 claims
Johnson & JohnsonXarelto$202$16,55914 claims
Lilly USA, LLCTrulicity$33$12,21113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →